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ABSTRACT
Colorectal cancer develops in a multi-step process and is associated with genetic alterations. Blocking apoptosis is a key
factor to unlimited cell proliferation and immortalization. Survivin expression inhibits the programmed cell death process,
apoptosis. This molecule could play a potential role in cancer development. Survivin is an attractive target for clinical trials to
develop cancer treatment. RNA was prepared from colorectal tumor and adjacent non-tumor tissues and then transcribed to
complementary DNA. Human survivin mRNA levels were quantitatively measured by real time polymerase chain reaction
(PCR) in tumor and adjacent non-tumor tissues. Expression levels of survivin mRNA in adenocarcinomas were significantly
higher than in non-tumor mucosa (p < 0.0001). The expressions of survivin mRNA in adenocarcinomas were related to the
degree of differentiation (survivin; p=0.034). No difference was found with other clinicopathological features. These findings
indicate survivin role in colorectal carcinogenesis. Survivin could be used as a potential diagnostic and prognostic marker in
colorectal cancer. Successful inhibition of this molecule could lead to the development of a new drug for cancer therapy.
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INTRODUCTION
Colorectal cancer is one of the most common cancers
in the western world. It develops in a multi-step
process and is associated with genetic alteration.
Adenomatous polyposis emerges due to mutations
in the Adenomatosis Polyposis Coli (APC) gene.
Accumulation of additional mutations in tumor
suppressor genes or cell cycle control genes can
contribute to increasing the risk of polyps
progressing toward adenocarcinoma (Vogelstein and
Kinzler, 1993; Vogt, 1993). This complex genetic
process could block apoptosis, a programmed cell
death, and ultimately leads to unlimited cell
proliferation.
Survivin is a member of the inhibitor of
apoptosis protein (IAP) family (Altieri, 2001). It is
a bifunctional protein involved in regulation of cell
proliferation and suppression of apoptosis. Survivin
is expressed in embryonic tissues but undetectable
in most normal differentiated tissues (Ambrosini
et al., 1997; Adida et al., 1998). Survivin is also
upregulated in most tumors and it’s over expression,
which may be due to promoter mutation, may allow
abnormally divided cells to overcome cell cycle
checkpoints during mitosis (Ambrosini et al., 1997).
However, the inhibition mechanism of apoptosis by
survivin is not clear. A high survivin expression
level was detected in different human tumors: breast
cancer, gastric cancer, lung cancer, pancreatic
cancer and colon cancer. These studies found no
correlation with clinicopathological features but a
prognostic value of survivin expression (Kawasaki
et al., 1998; Kami et al., 2004; Meng et al., 2004;
Span et al., 2004; Atikcan et al., 2006).
In this study, expression levels of survivin
mRNA in colorectal tissues was quantitatively
investigated by real time polymerase chain reaction
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(PCR). Additionally, survivin expression was
correlated with the clinicopathological features of
the cancer tissue samples.
MATERIALS AND METHODS
Patient selection and sample collection
Patients with histologically confirmed colon
and rectal tumors were prospectively and
consecutively recruited into the study. Patients who
had pre-operative adjuvant chemo or radiotherapy
were excluded. Consent was obtained according
to the hospital human ethics committee approval.
The clinical diagnostic, staging, surgical, and
pathological data were collected in a standardized
manner, using a computerized database. At the time
of surgery, the tissue from the tumor and normal
colorectal mucosa from the proximal resection
margin were promptly sampled from the resected
specimen. These samples were preserved in
RNAlater within 10 minutes of surgery to prevent
degradation of the RNA and then stored at –20ºC.
RNA extraction
Total RNA was extracted from the 10-25 mg of
tested tissue by disruption and homogenization
using High Pure RNA Tissue Kit (Roche Diagnostics,
Mannheim, Germany). DNase I was used to digest
DNA contamination. The quality of the RNA was
checked by agarose gel electrophoresis to rule out
degraded RNA.
cDNA preparation
Purified total RNA was reverse transcribed in a
total volume of 25 μl using random primer at a ratio
of 2 to 1 RNA and transcriptor reverse transcriptase
(Roche Diagnostics, Mannheim, Germany). The
reaction mixture was incubated for 10 min at 25ºC
first, 60 min at 50ºC, and followed by enzyme
inactivation step for 5 min at 85ºC. The cDNA
samples were stored at –20ºC until use.
Real time quantification PCR
The rotor gene system (Corbett Research,
Sydney, Australia) was used to run real-time
quantification polymerase chain reaction. Absolute
quantification assay was chosen to analyze
survivin (target), and glyceraldehydes 3-phosphate
dehydrogenase (GAPDH, endogenous control)
mRNA expression. PCR was performed in a total
volume of 20 μl reaction mixture containing 1x
TaqMan universal master mix with AmpErase uracil
N-glycosylase (Applied Biosystems, Foster City,
USA) 600nM of each primer, 200nM TaqMan probe,
and 2 μl of unknown cDNA or 2 μl of standard
template. All the samples (unknown and standard)
were run in duplicate and accompanied by a non-
template control. Thermal cycling conditions
included 2 min at 50ºC and 10 min at 95ºC,
followed by 45 cycles at 95ºC for 15 sec and 60ºC
for 60 sec.
Primers and probes
The primer set and probe for amplification
of survivin (GeneBank accession number
NM_001168), and GAPDH, (GenBank accession
number NM_002046) mRNA were designed using
GenScript web site/design tool (www.genscript.
com/ssl-bin/app/primer) (Table 1). The primers for
the genes placed in different exons, were checked
by conventional PCR to ensure these did not
amplify genomic DNA. The probes contained 6-
carboxyflourscein (FAM) as a fluorescent reporter
dye, and 6-carboxytetramethyl-rhodamine (TAMRA)
as the quencher for its light emission spectrum.
These probes were purchased from Sigma Genosys
(Wollands, TX, USA). During the extension phase
of PCR, the probe hybridized to the target sequence
and was then cleaved due to the 5’ to 3’ exonuclease
activity of Taq polymerase. The increase in
fluorescent signal of the reporter was proportional
to the amount of specific PCR products, providing
highly accurate and reproducible quantification.
Standard curve
For absolute quantitation assay, a standard
curve was constructed from a known concentration
of DNA sample. A segment of 290 bp survivin gene
was generated by conventional RT-PCR. The PCR-
product was checked on agarose gel for unspecific
amplification, purified by High Pure PCR Product
Kit (Roche Diagnostics, Mannheim, Germany),
and then accurately quantified by ultraviolet-
spectrophotometer. The concentration of the
known DNA sample was converted to molecules per
microliter. This known standard sample was
adjusted to 0.8x1010 molecule/μl and then serially
diluted by 1/10 down to 0.8x10. Two μl of each
dilution (106 to 101) in duplicate was used as a
template for real time PCR.
For each sample, the expression level of
survivin, and GAPDH mRNA were quantified as
a copy number (per reaction) using the standard
curve (Fig. 1). Expression level of survivin for each
sample was normalized by dividing by the copy
number of GAPDH (Normalization = copy number
of target genesample / copy number of GAPDHsample
x100).
Statistical Analysis
The expression difference between the tumor
and matched non-tumor samples was done using t-
test. Correlation between expression level and
clinicopathological features of the patients was
analyzed by Mann-Whitney tests. The significance
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Table 1. PCR primers and probes used for quantitation of survivin and GAPDH
Primer Sequence Amplicon size, bp
Survivin 120
Upper 5’-AAGGACCACCGCATCTCTAC-3’
Lower 5’-CAAGTCTGGCTCGTTCTCAG-3’
Probe 5’-(FAM) CAGCCCTCCAAGAAGGGCCA (TAMRA)-3’
GAPDH 79
Upper 5’-ATGGGTGTGAACCATGAGAA-3’
Lower 5’-GTGCTAAGCAGTTGGTGGTG-3’
Probe 5’-(FAM) CCTCAAGATCATCAGCAATGCCTCC (TAMRA)-3’
Fig. 1. Standard curve, generated by rotor gene, of serially dilution of known concentration
of survivin segment (1.6x101-1.6x106). The threshold cycle (CT) of each dilution was plotted
against concentration.
level was taken at p<0.05. All statistical tests were
performed with the Statistical Package for Social
Sciences (SPSS version 14.0, Chicago, IL).
RESULTS
Fourty seven patients (28 Males and 19 Females)
with colorectal adenocarcinomas were recruited in
this study. The age of the patients was 37 to 90 years
(mean 66.45).
Expression level of survivin mRNA was
analyzed quantitatively by real time PCR. All the
tumor tissue samples expressed survivin mRNA and
the expression of survivin mRNA in tumor tissues
was 100% higher when compared with the
expressions in non-tumor tissues. The level of
survivin expressed in tumor tissue samples was more
than four times in comparison with non-tumor
tissues (Fig. 2).
The expression level of survivin mRNA in
tumor tissues was higher than in matched adjacent
non-tumor tissue samples and statistically
significant (p<0.0001, t-test).
At the same time, expressions of survivin mRNA
were higher in poorly differentiated samples than
in well and moderate differentiated samples. A
significant relationship was found between
differentiation and tumor expression of survivin
(p=0.034). Other clinical data revealed no
significance was found with the expression of
survivin gene (Table 2).
DISCUSSION
The expression of survivin mRNA was investigated
in colorectal tissue cancer. The molecule has a
characteristic function which is essential for cancer
cells to continue proliferation indefinitely. Survivin
interacts either with caspases (-3, -7, -9) and/or p53
to block the programmed cell death (apoptosis) (Sah
et al., 2006).
Real time PCR technique was used to quantitate
the expression levels of hTERT and survivin mRNA.
This technique is specific, and sensitive enough
to detect mRNA molecules even in a single
cell (Bustin, 2000; De Kok et al., 2000). Also,
quantitative evaluation makes statistical analysis
more appropriate.
Survivin was detected in colorectal
adenocarcinomas and adjacent non-tumor tissues.
Expression level of survivin mRNA in tumor tissues
was 100% higher than in non-tumor tissues. It
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Table 2. Expression level of survivin mRNA and correlation with clinicopathological features for the patients
with colorectal cancer
                 Expression of Survivin
Variable No (%)                   Mucosa                     Tumor P value*
Mean Range Mean Range
Gender n.s
Male 28 (60) 1.330 0.24–2.61 5.186 1.92–7.16
Female 19 (40) 1.147 0.39–2.21 5.175 2.82–7.44
Age n.s
<65 20 (43) 1.322 0.24–2.21 5.346 1.92–7.16
>65 27 (57) 1.207 0.31–2.61 5.060 3.03–7.44
Site n.s
Colon 31 (66) 1.167 0.24–2.21 5.183 1.92–7.44
Rectum 16 (34) 1.429 0.47–2.61 5.180 3.03–7.09
Differentiation 0.034
Well+Moderate 38 (81) 1.275 0.24–2.61 5.042 2.25–7.44
Poor 09 (19) 1.176 0.38–2.19 5.773 1.92–7.16
Stage n.s
I+II 29 (62) 1.333 0.31–2.61 5.022 2.25–6.89
III+IV 18 (38) 1.132 0.24–2.19 5.440 1.92–7.44
*Mann-Whitney test.
has been reported that expression and localization
of survivin in normal colonic mucosa was restricted
to the bottom of crypts (Gianani et al., 2001). In
the literature, while survivin expression in
adenocarcinomas was up-regulated, a contradictory
result of survivin expression in normal mucosa was
reported (Kawasaki et al., 1998; Gianani et al.,
2001). Detection of survivin was approached
either by immunohistochemistry staining, in situ
hybridization and/or RT-PCR. Some studies showed
no survivin was detected in normal colonic mucosa
(Kawasaki et al., 1998; Kawasaki et al., 2001; Sarela
et al., 2001). Others studies found survivin
expressed in normal mucosa (Sarela et al., 2000;
Fig. 2. Expression level of survivin mRNA (mean±SD) in colorectal
tissue samples.
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Gianani et al., 2001; Zhang et al., 2001). These
discrepancies were explained by either the specimen
contamination with a component of non-epithelial
tissue that possibly hindered the detection of
survivin, or the difference in the sensitivity of the
methods used for detection (Zhang et al., 2001). We
found expression of survivin mRNA in normal
mucosa was consistent with the previous reports
(Sarela et al., 2000; Gianani et al., 2001; Zhang et
al., 2001). This low level of survivin mRNA could
represent expression of colonic stem cells at the
bottom of basal crypt. This expression may be
essential for these colonic stem cells to maintain
normal proliferation activities before their
differentiation and migration to the top of crypt.
Survivin which is expressed in different types
of cancer is a potential target for anti-cancer
treatment development strategies. Correlation
between survivin expression and clinico-
pathological parameters could lead to the prediction
of cancer development. In colorectal cancer,
survivin was detected in 53% to 100% of tumor
samples (Kawasaki et al., 1998; Sarela et al., 2000;
Gianani et al., 2001). It has been reported that
survivin expression increases during development
of colorectal tumorigenesis (Kawasaki et al., 2001)
but no correlation was found with clinico-
pathological features (Kawasaki et al., 1998; Sarela
et al., 2000; Sarela et al., 2001). However, survivin
expression has been reported as a prognostic factor
of poor outcome in colorectal carcinoma (Kawasaki
et al., 1998; Sarela et al., 2001), as well as not being
a specific marker of colorectal adenocarcinomas
(Gianani et al., 2001).
In this study, survivin mRNA was detected in
all tumor samples and expression level was four
times higher than in normal tissues. The degree of
differentiation or tumor grade was considered as low
grade (well and moderately differentiated) and high
grade (poorly differentiated and undifferentiated).
This stage independent prognostic factor showed a
significant increase of survivin mRNA was found in
tumor samples with poor differentiation (p=0.034).
This is the first study reporting a significant
statistical relationship between expression of
survivin mRNA and the degree of tumor
differentiation in colorectal cancer. It has been
reported that the expression of survivin in breast
cancer also correlated with histological grade, stage
and lymph metastasis (Sohn et al., 2006). These
results indicate the diagnostic and possibly
prognostic role of survivin in the pathology of
colorectal cancer and the possibility of targeting
survivin as a goal for anti-cancer therapy.
In conclusion, Survivin mRNA expression in
colorectal tissues was quantitatively explored by
real time PCR. The expression levels of survivin in
adenocarcinomas were different from adjacent non-
tumor mucosa, and correlated with the degree of
differentiation.
These findings indicate the significant
importance of survivin molecule in pathology of
cancer and could be used as a potential diagnostic
and prognostic markers as well as an indication for
possible cancer treatment.
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